PE ratio relative to earnings growth — is the valuation justified?
| Symbol | Company | PEG | P/E | Growth | vs OTSKY |
|---|---|---|---|---|---|
| ALPMY | Astellas Pharma Inc. | 0.00 | 0.1 | 21.6% | — |
| DSNKY | Daiichi Sankyo Company, Limited | 0.00 | 0.1 | 30.6% | — |
| CHGCY | Chugai Pharmaceutical Co., Ltd. | 0.00 | 0.2 | 33.4% | — |
| NVS | Novartis AG | 1.51 | 23.3 | 15.4% | — |